News for Catalyst Pharmaceuticals, Inc. (CPRX)

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Catalyst Pharmaceuticals Inc (CPRX). The firm reduced its ho

CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (”œCatalyst” or ”œCompany”) ( CPRX), a commercial-stage biopharmac

**media[608305]**

We recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against stocks with consistent growth to buy now. The market is clouded by friction between trading partners. But even at these uncertain times, one […]

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ('Catalyst' or 'Company') (Nasdaq: CPRX), a commercial-st...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against other best Russell 2000 stocks to buy according to Wall Street analysts. Since President Trump announced new tariffs, the […]

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc.

Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 Growth Index generated a return of 1.7% in the fourth quarter, bringing the yearly returns to 15.2%. The portfolio generated positive returns in the fourth quarter […]

Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Inc (CPRX), a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel medicines for rare and diffi

CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") ( CPRX), a commercial-stage biopharmaceutical

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Total Revenue (2024): $491.7 million, a 23.5% increase year over year.Net Product Revenue (2024): $489.3 million, a 23.4% increase over 2023.Q4 2024 Total Reve

Strengths highlight Catalyst Pharmaceuticals Inc's unique product offerings and market penetration.Weaknesses and challenges underscore the need for strategic

Feb 27, 2025 / 01:30PM GMTOperator Greetings and welcome to the Catalyst Pharmaceuticals fourth quarter in full year 2024 financial results conference call. (Op

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsMichael Kalb - Executive Vice...

Catalyst Pharmaceuticals Inc (CPRX) announced its financial results for the fourth quarter and full year of 2024, reporting a record total revenue of $491.7 mil

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Stro